Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 20/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4196978 | 0.91 | KISS1R (0.64) | KISS1R | |
| SCHEMBL4208396 | 0.89 | KISS1R (0.61) | KISS1R | |
| SCHEMBL4208047 | 0.89 | KISS1R (0.57) | KISS1R | |
| SCHEMBL4200696 | 0.87 | KISS1R (0.64) | KISS1R | |
| SCHEMBL4216630 | 0.87 | KISS1R (0.64) | KISS1R | |
| SCHEMBL5015337 | 0.86 | KISS1R (0.68) | KISS1R | |
| SCHEMBL4206368 | 0.85 | KISS1R (0.63) | KISS1R | |
| SCHEMBL4210056 | 0.84 | KISS1R (0.62) | KISS1R | |
| SCHEMBL4204527 | 0.83 | KISS1R (0.63) | KISS1R | |
| SCHEMBL4209981 | 0.82 | KISS1R (0.75) | KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703459-B2 | Catalytic domains of beta(1,4)-galactosyltransferase I having altered metal ion specificity | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2014-04-22 | — | — | US | claimed |
| US-20080199905-A1 | Catalytic Domains Of Beta(1,4)-Galactosyltransferase I Having Altered Metal Ion Specificity | GOVERMENT OF THE US, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-08-21 | — | — | US | claimed |
| US-8703459-B2 | Catalytic domains of beta(1,4)-galactosyltransferase I having altered metal ion specificity | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2014-04-22 | — | — | US | disclosed |
| US-20090233345-A1 | Catalytic domains of beta(1,4)-galactosyl transferase i having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use | Govt. of the US, as represented by the secretary, Dept. of Health and Human Services (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090156646-A1 | PYRIDYLPHENOL COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-7482133-B2 | Catalytic domains of β(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-01-27 | — | — | US | disclosed |
| US-20080199905-A1 | Catalytic Domains Of Beta(1,4)-Galactosyltransferase I Having Altered Metal Ion Specificity | GOVERMENT OF THE US, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-08-21 | — | — | US | disclosed |
| EP-1921066-A1 | PYRIDYLPHENOL COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-05-14 | — | — | EP | disclosed |
| US-20060084162-A1 | Catalytic domains of beta(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156646-A1 | PYRIDYLPHENOL COMPOUND AND USE THEREOF | GNRHR, PGR, MC1R | KISS1R 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.